Virios Therapeutics Inc Stock News

- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®- - New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® - ATLANTA, GA / ACCESS Newswire / December 2, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"...

- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled ...

- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release -

ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and neuropathy, announced today that it will report third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeuti...

ATLANTA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathic disorders, today announces that Greg Duncan, Chief Executive Officer will participate at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 - 23, 202...

ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the Halneuron®(tetrodotoxin) pain management research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025. ...

Dogwood Therapeutics, Inc. - Special Call Company Participants Greg Duncan - Chairman & CEO R. Gendreau - Chief Medical Officer Conference Call Participants Xun Lee - H.C.

-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026-